Issue Information

Issue Information
Published: (2025)

Issue Information
Published: (2025)

Issue Information
Published: (2025)

Issue Information
Published: (2025)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2026)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2026)

Issue Information
Published: (2024)

Issue Information
Published: (2026)

Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition
by: Anna Ossami Saidy, et al.
Published: (2025)

Cell‐free DNA for detection and monitoring of extramedullary AML relapse
by: Henri C. Hupe, et al.
Published: (2025)

Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
by: Jan‐Niklas Eckardt, et al.
Published: (2025)

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRD neg remission after intensive induction
by: Konstanze Döhner, et al.
Published: (2025)

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
by: David A. Sallman, et al.
Published: (2025)

TET3 regulates hematopoietic stem cell homeostasis during embryonic and adult hematopoiesis
by: Harmony C. Ketchum, et al.
Published: (2025)

Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
by: Uwe Platzbecker, et al.
Published: (2025)

HELIOS Action: Advancing research, education, and equity in hemoglobinopathies across Europe and beyond
by: Sotiroula Chatzimatthaiou, et al.
Published: (2025)

MMS22L is a novel key actor of normal and pathological erythropoiesis
by: Elia Colin, et al.
Published: (2025)

Correction to “Quality of vitamin K antagonist treatment during the last year of life”
Published: (2025)

Publication Only
Published: (2025)

Mutational signatures and kataegis in pediatric B‐cell precursor acute lymphoblastic leukemia
by: Rebeqa Gunnarsson, et al.
Published: (2025)

Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
by: Mwanasha H. Merrill, et al.
Published: (2025)

Patterns of immune recovery after axicabtagene ciloleucel for aggressive B‐cell lymphoma
by: André Airosa Pardal, et al.
Published: (2025)

Minimal residual disease assessment following CD19‐targeted therapy in B‐cell precursor acute lymphoblastic leukemia using standardized 12‐color flow cytometry: A EuroFlow study
by: Martijn W. C. Verbeek, et al.
Published: (2025)

Dynamic evolution of TCF3‐PBX1 leukemias at the single‐cell level under chemotherapy pressure
by: Mira Kusterer, et al.
Published: (2025)

Correction to “Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network”
Published: (2025)

Can health inequalities in sickle cell disease be addressed through novel therapies?
by: Stephen P. Hibbs, et al.
Published: (2025)

Low‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients
by: Shoshana Burke, et al.
Published: (2025)

Monitoring outcomes in patients treated by ATMPs
by: Kostas Konstantopoulos
Published: (2025)

Correction to “Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up”
Published: (2025)